The Division of Cancer Prevention supports major scientific collaborations, research networks, investigator-initiated grants, postdoctoral training, and specialized resources across the United States.
Alliance of Glycobiologists for Cancer Research
Nine Tumor Glycomics Laboratories working to reveal cancer-related dynamics of complex carbohydrates.
Barrett's Esophagus Translational Research Network (BETRNet)
A multi-disciplinary, multi-institutional collaboration to enhance understanding of Barrett's esophagus and to prevent esophageal adenocarcinoma.
Cancer Prevention Clinical Trials Network (CP-CTNet)
CP-CTNet performs early phase clinical trials to assess the preventive potential of agents and interventions of varying classes, many of which target molecules and processes known to be important during carcinogenesis.
Cancer Prevention Fellowship Program (CPFP)
Training to form a strong foundation in cancer prevention and control for scientists and clinicians.
Consortium for Imaging and Biomarkers (CIB)
Eight lead investigators combining imaging methods for the visualization of lesions with biomarkers to improve the accuracy of screening, early cancer detection, and the diagnosis of early stage cancers.
Consortium for Molecular Characterization of Screen-Detected Lesions
Seven laboratories and a coordinating center focused on identifying screening-detected pre-cancers and early cancers, including within the tumor microenvironment.
Early Detection Research Network (EDRN)
Comprehensive infrastructure and resources critical to discovery, development and validation of biomarkers for cancer risk and early detection.
Liquid Biopsy Consortium
A new, noninvasive technique that can detect disease biomarkers in blood, urine, and sputum.
NCI Community Oncology Research Program (NCORP)
A clinical trials network of cancer care professionals who care for diverse populations across the United States.
Pancreatic Cancer Detection Consortium (PCDC)
Develops and tests new molecular and imaging biomarkers to detect early stage PDAC and its precursor lesions.
Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
Systematic early clinical development of promising preventive agents through five major medical research centers.
PREVENT Cancer Preclinical Drug Development Program (PREVENT)
Research pipeline for new prevention interventions and biomarkers headed toward clinical trials.
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)
A repository of data from a large randomized trial on the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74.
Small Cell Lung Cancer (SCLC) Consortium
Conducting research to expand the understanding of the critical molecular changes in the lung that precede the development of frank SCLC and/or to identify populations at particularly high risk for SCLC.
Supportive Care and Symptom Management
Examining symptoms and morbidities related to cancer, its treatment, quality of life and end of life.
Translational Liver Cancer (TLC) Consortium
Conducting studies to improve surveillance of liver cancer in high-risk populations, increase detectability at early stages, and stratify at-risk patients.
US-Latin American-Caribbean Clinical Trials Network (ULACNet)
ULACNet, proposed to be established through the funding opportunity RFA-CA-18-018, will focus on improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals.
Research Networks Map
The Division of Cancer Prevention supports major scientific collaborations and research networks at more than 100 sites across the United States.